Loading...
Loading...
Analysts at Morgan Stanley initiated coverage on shares of Myriad Genetics
MYGN with a Underperform rating.
The target price for Myriad Genetics is set to $25.
Myriad Genetics shares have gained 29.61% over the past 52 weeks, while the S&P 500 index has surged 14.68% in the same period.
Myriad Genetics' shares fell 1.98% to $34.20 in pre-market trading.
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in